VEGFA and cardiomyopathy: Inhibition of the vascular endothelial growth factor (VEGF) signaling pathway (VSP) is responsible for preventing tumor angiogenesis and has been associated with various cardiovascular toxicities including cardiomyopathy, hypertension, arterial and/or venous thrombosis, and renal vascular injury [27].